Avertix Medical Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Avertix Medical Inc.
News We’re Watching: AngelMed Becomes Avertix, 3M Layoffs, FDA Warns On COVID Test Use
This week, cardiac monitoring firm AngelMed announced its new name; Tempus nabbed FDA approval for its tumor profiling test; and iRhythm revealed that it’s been subpoenaed by the US Department of Justice.
Exec Chat: AngelMed Rolls Out Guardian Cardiac Monitor, Prepares To Go Public
Angel Medical Systems accomplished several major milestones in 2021, including FDA approval of the second-generation version of The Guardian implantable cardiac detection monitor and patient-warning system for acute coronary syndrome events. CEO Brad Snow talked to Medtech Insight about the company's plans to commercialize The Guardian in 2022.
Victory From The Jaws Of Defeat: Angel Med Wrests Approval For Implantable Heart-Attack Monitor
A US FDA advisory panel unanimously voted down the AngelMed cardiac monitor two years ago. But venture-backed Angel Medical Systems was able to engage with the agency after the panel, and the firm ultimately achieved approval of the device designed to help detect heart attacks earlier. It’s a lesson in firms leveraging all the data they have at their disposal.
Global Device Approvals, Weekly Snapshot: April 9-15, 2018
A snapshot of global medical device and diagnostics approvals recorded during the past week in Medtech Insight's Approvals Tracker.
- Implantable Devices
- Monitoring Equipment & Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- Angel Medical Systems, Inc.
- Angel Medical
- Angel Medical Systems
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.